


DESCRIPTION	
Species Reactivity	Mouse
Specificity	Detects mouse CCL9/10/MIP-1 γ in ELISAs and Western blots. In sandwich ELISAs, less than 0.02% cross-reactivity with recombinant human CCL3, 4, 15, 19, 20, recombinant mouse CCL3, 4, 19, or recombinant rat CCL20 is observed.
Source	Monoclonal Rat IgG ₁ Clone # 62105
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant mouse CCL9/10/MIP-1 γ Gln22-Gln122 Accession # P51670
Endotoxin Level	<0.10 EU per 1 μ g of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 μ m filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	1 μ g/mL	Recombinant Mouse CCL9/10/MIP-1 γ (Catalog # 463-MG) under non-reducing conditions only
Mouse CCL9/10/MIP-1γ Sandwich Immunoassay		Reagent
ELISA Capture	2-8 μ g/mL	Mouse CCL9/10/MIP-1 γ Antibody (Catalog # MAB463)
ELISA Detection Standard	0.1-0.4 μ g/mL	Mouse CCL9/10/MIP-1 γ Biotinylated Antibody (Catalog # BAF463) Recombinant Mouse CCL9/10/MIP-1 γ (Catalog # 463-MG)
Neutralization		Measured by its ability to neutralize CCL9/10/MIP-1 γ -induced chemotaxis in the BaF3 mouse pro-B cell line transfected with human CCR1. The Neutralization Dose (ND ₅₀) is typically 1-4 μ g/mL in the presence of 0.04 μ g/mL Recombinant Mouse CCL9/10/MIP-1 γ .

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Mouse CCL9/10 (also named MIP-1 γ and MRP-2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the β (or CC) intercrine family of chemokines (1-3). Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteine-containing CC subfamily of chemokines (2, 4, 5). This subfamily contains four N-terminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no human-to-rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded N-terminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines (3-7). Mouse CCL9/10 is 75% aa identical to rat CCL9/10 (8). Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at full-length, but are converted to highly active forms upon N-terminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the N-terminus, generating a highly active, 8 kDa, 71-73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP-1 α and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a full-length molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants (5, 7).

References:

1. Zlotnik, A. and O. Yoshie (2000) *Immunity* **12**:121.
2. Zlotnik, A. *et al.* (1999) *Crit. Rev. Immunol.* **19**:1
3. Mohamadzadeh, M. *et al.* (1996) *J. Immunol.* **156**:3102.
4. Haelens, A. *et al.* (1996) *Immunobiology* **195**:499.
5. Berahovich, R.D. *et al.* (2005) *J. Immunol.* **174**:7341.
6. Youn, B-S. *et al.* (1995) *J. Immunol.* **155**:2661.
7. Poltorak, A.N. *et al.* (1995) *J. Inflamm.* **45**:207.